Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zhou, Yue ^a   Yamada, Naoki ^b   Tanaka, Tomohiro ^a   Hori, Takashi ^b   Yokoyama, Satoru ^a   Hayakawa, Yoshihiro ^a   Yano, Seiji ^c   Fukuoka, Junya ^d   Koizumi, Keiichi ^a   Saiki, Ikuo ^a   Sakurai, Hiroaki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOYAMA UNIVERSITY HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; EPHRIN A1; EPHRIN RECEPTOR A2; F ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; SERINE; TRAMETINIB; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; VEMURAFENIB; ZINC ION; AUTACOID; CYTOKINE; RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3; RPS6KA1 PROTEIN, HUMAN; S6 KINASE;

AMINO ACID; CANCER; CELLS AND CELL COMPONENTS; CHEMICAL REACTION; ENZYME ACTIVITY; GENE EXPRESSION; LIGAND; MOTILITY; SMOKING; SURVIVAL; TUMOR;

ARTICLE; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CATALYSIS; CELL DEATH; CELL MIGRATION; CELL MOTILITY; CELL PERMEABILIZATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; FEMALE; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; MOLECULARLY TARGETED THERAPY; NEGATIVE FEEDBACK; ONCOGENE; OSMOTIC STRESS; OVERALL SURVIVAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; TUMOR MICROENVIRONMENT; BREAST TUMOR; CELL MOTION; GENETICS; HEK293 CELL LINE; LIVER TUMOR; LUNG TUMOR; MALE; METABOLISM; NEOPLASM; NON SMALL CELL LUNG CANCER; PHOSPHORYLATION; PROGNOSIS; PROSTATE TUMOR; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CATALYSIS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOKINES; FEMALE; HEK293 CELLS; HELA CELLS; HUMANS; INFLAMMATION MEDIATORS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASMS; PHOSPHORYLATION; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, EPHA2; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SERINE; SIGNAL TRANSDUCTION;

EID: 84937019863     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8679     Document Type: Article

References (55)

1. Bennasroune, A., Gardin, A., Aunis, D., Cremel, G. & Hubert, P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit. Rev. Oncol. Hematol. 50, 23-38 (2004).
2. Templeton, A. J. et al. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. Cancer Treat. Rev. 40, 1048-1055 (2014).
3. Miao, H. & Wang, B. Eph/ephrin signaling in epithelial development and homeostasis. Int. J. Biochem. Cell Biol. 41, 762-770 (2009).
4. Miao, H. & Wang, B. EphA receptor signaling-complexity and emerging themes. Semin. Cell Dev. Biol. 23, 16-25 (2012).
5. Tandon, M., Vemula, S. V. & Mittal, S. K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin. Ther. Targets 15, 31-51 (2011).
6. Huang, J. et al. EphA2 promotes epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in gastric cancer cells. Oncogene 33, 2737-2747 (2014).
7. Binda, E. et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22, 765-780 (2012).
8. Amato, K. R. et al. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J. Clin. Invest. 124, 2037-2049 (2014).
9. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
10. Red Brewer, M. et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol. Cell 34, 641-651 (2009).
11. Singhirunnusorn, P. et al. Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-alpha through the TAK1-p38 signaling pathway. J. Biol. Chem. 282, 12698-12706 (2007).
12. Nishimura, M. et al. TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-kB-independent survival pathways in tumor necrosis factor alpha signaling. Mol. Cell Biol. 29, 5529-5539 (2009).
13. Sato, K. et al. Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Cancer Sci. 104, 1315-1322 (2013).
14. Zakrzewska, M. et al. ERK-mediated phosphorylation of fibroblast growth factor receptor 1 on Ser777 inhibits signaling. Sci. Signal 6, ra11 (2013).
15. Lonic, A. et al. Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation. J. Biol. Chem. 288, 14874-14885 (2013).
16. Nadratowska-Wesolowska, B. et al. RSK2 regulates endocytosis of FGF receptor 1 by phosphorylation on serine 789. Oncogene 33, 4823-4836 (2014).
17. Li, X. et al. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumour Biol. 31, 477-488 (2010).
18. Miao, H. et al. EphA2 mediates ligand-dependent inhibition and ligandindependent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20 (2009).
19. Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261-D270 (2012).
20. Kinoshita, E. & Kinoshita-Kikuta, E. Improved Phos-tag SDS-PAGE under neutral pH conditions for advanced protein phosphorylation profiling. Proteomics 11, 319-323 (2011).
21. Sakurai, H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 30, 522-530 (2012).
22. Obata, T. et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J. Biol. Chem. 275, 36108-36115 (2000).
23. Cargnello, M. & Roux, P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50-83 (2011).
24. Sapkota, G. P. et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 401, 29-38 (2007).
25. Li, P. et al. P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Mol. Biol. Cell 23, 1582-1592 (2012).
26. Lara, R., Seckl, M. J. & Pardo, O. E. The p90 RSK family members: common functions and isoform specificity. Cancer Res. 73, 5301-5308 (2013).
27. Sulzmaier, F. J. & Ramos, J. W. RSK isoforms in cancer cell invasion and metastasis. Cancer Res. 73, 6099-6105 (2013).
28. Reungwetwattana, T., Weroha, S. J. & Molina, J. R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin. Lung Cancer 13, 252-266 (2012).
29. Cantwell-Dorris, E. R., O'Leary, J. J. & Sheils, O. M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 10, 385-394 (2011).
30. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
31. Poulikakos, P. I. et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
32. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114 (2012).
33. Brannan, J. M. et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin. Cancer Res. 15, 4423-4430 (2009).
34. Wang, J. et al. Expression of EphA1 in gastric carcinomas is associated with metastasis and survival. Oncol. Rep. 24, 1577-1584 (2010).
35. Chen, G. et al. EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma. Oncol. Rep. 23, 563-570 (2010).
36. Doehn, U. et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol. Cell 35, 511-522 (2009).
37. Woo, M. S., Ohta, Y., Rabinovitz, I., Stossel, T. P. & Blenis, J. Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol. Cell Biol. 24, 3025-3035 (2004).
38. Gawecka, J. E. et al. RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration. J. Biol. Chem. 287, 43424-43437 (2012).
39. Brantley-Sieders, D. M. et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 118, 64-78 (2008).
40. Hiramoto-Yamaki, N. et al. Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. J. Cell Biol. 190, 461-477 (2010).
41. Harada, K., Hiramoto-Yamaki, N., Negishi, M. & Katoh, H. Ephexin4 and EphA2 mediate resistance to anoikis through RhoG and phosphatidylinositol 3-kinase. Exp. Cell Res. 317, 1701-1713 (2011).
42. Kawai, H. et al. Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2. FEBS Open Bio 3, 78-82 (2013).
43. Miao, H. et al. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene 34, 558-567 (2015).
44. Stratford, A. L. et al. Targeting p90 ribosomal S6 kinase eliminates tumorinitiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 30, 1338-1348 (2012).
45. Brannan, J. M. et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev. Res. (Phila.) 2, 1039-1049 (2009).
46. Kinch, M. S., Moore, M. B. & Harpole, Jr. D. H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 9, 613-618 (2003).
47. DeMarini, D. M. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat. Res. 567, 447-474 (2004).
48. Arul, N. & Cho, Y. Y. A rising cancer prevention target of RSK2 in human skin cancer. Front. Oncol. 3, 201 (2013).
49. Udayakumar, D. et al. EphA2 is a critical oncogene in melanoma. Oncogene 30, 4921-4929 (2011).
50. Paraiso, K. H. et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 5, 264-277 (2015).
51. Miao, B. et al. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 5, 274-287 (2015).
52. Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877-1888 (2014).
53. Wang, Y. et al. Negative regulation of EphA2 receptor by Cbl. Biochem. Biophys. Res. Commun. 296, 214-220 (2002).
54. Tanaka, M. et al. Tiam1 mediates neurite outgrowth induced by ephrin-B1 and EphA2. EMBO J. 23, 1075-1088 (2004).
55. Katayama, K., Yoshioka, S., Tsukahara, S., Mitsuhashi, J. & Sugimoto, Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol. Cancer Ther. 6, 2092-2102 (2007).